Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Baxter
Merck
Colorcon
Boehringer Ingelheim

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR NUVIGIL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Nuvigil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00078325 ↗ Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS) Completed Cephalon Phase 3 2004-02-01 The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings (as related to general condition) at week 12, or last post-baseline visit.
NCT00373672 ↗ Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed Cephalon Phase 4 2006-08-01 This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.
NCT00373672 ↗ Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed National Alliance for Research on Schizophrenia and Depression Phase 4 2006-08-01 This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.
NCT00373672 ↗ Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed Vanderbilt University Phase 4 2006-08-01 This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.
NCT00373672 ↗ Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed Vanderbilt University Medical Center Phase 4 2006-08-01 This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.
NCT00555347 ↗ Use of Armodafinil for Fatigue in Sarcoidosis Completed Cephalon Phase 2/Phase 3 2007-10-01 To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.
NCT00555347 ↗ Use of Armodafinil for Fatigue in Sarcoidosis Completed University of Cincinnati Phase 2/Phase 3 2007-10-01 To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nuvigil

Condition Name

Condition Name for Nuvigil
Intervention Trials
Fatigue 7
Depression 4
Obstructive Sleep Apnea 3
Head And Neck Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nuvigil
Intervention Trials
Fatigue 12
Depressive Disorder, Major 4
Depressive Disorder 4
Depression 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nuvigil

Trials by Country

Trials by Country for Nuvigil
Location Trials
United States 146
Canada 5
Ukraine 4
South Africa 3
Argentina 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nuvigil
Location Trials
Texas 11
New York 9
California 8
Massachusetts 8
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nuvigil

Clinical Trial Phase

Clinical Trial Phase for Nuvigil
Clinical Trial Phase Trials
Phase 4 5
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nuvigil
Clinical Trial Phase Trials
Completed 22
Terminated 5
Withdrawn 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nuvigil

Sponsor Name

Sponsor Name for Nuvigil
Sponsor Trials
Cephalon 13
National Cancer Institute (NCI) 7
M.D. Anderson Cancer Center 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nuvigil
Sponsor Trials
Other 34
Industry 21
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Moodys
AstraZeneca
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.